Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
103.4 USD | +0.54% | +1.45% | -6.03% |
May. 30 | U.S. FDA set to reorganize its food division starting October | RE |
May. 30 | Redburn Adjusts Price Target on Abbott Laboratories to $113 From $115 | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's high margin levels account for strong profits.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- With an expected P/E ratio at 29.75 and 25.62 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- With an enterprise value anticipated at 4.42 times the sales for the current fiscal year, the company turns out to be overvalued.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-6.03% | 179B | C+ | ||
+1.08% | 108B | C | ||
-2.19% | 69.03B | A | ||
-5.98% | 45.83B | B- | ||
+12.31% | 45.39B | B- | ||
+7.86% | 43.17B | B+ | ||
+15.98% | 29.89B | B | ||
+15.14% | 25.49B | A- | ||
-9.57% | 23.95B | A- | ||
-6.79% | 23.27B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ABT Stock
- Ratings Abbott Laboratories